Anti-tumor Activity
Anti-tumor Activity - Related Videos
04:13
A Technique to Assess the In Vivo Localization of Tumor-Specific Antibodies
0 Views •
2025
This video demonstrates a technique to study the in vivo localization of tumor-specific antibodies in a mouse tumor xenograft model. Upon subcutaneously injecting cancer cells into mice for tumor formation, fluorescently-labeled antibodies are injected that bind to tumor-specific receptors, enabling in vivo assessment of antibody localization via imaging.
09:05
Determining the Phagocytic Activity of Clinical Antibody Samples
0 Views •
Cited by 33 •
2011
We present a high-throughput flow cytometric assay to determine the phagocytic activity of antigen-specific antibodies from clinical samples, utilizing fluorescent antigen-coated beads and a monocytic cell line expressing multiple Fc receptors—providing receptor usage and phagocytic activity determinations in a standardized and reproducible fashion for any antigen of interest.
03:10
In Vivo Fluorescence Imaging to Localize Antibodies in a Mouse Tumor Xenograft Model
0 Views •
2025
The video demonstrates a fluorescence imaging method for in vivo antibody localization in a mouse tumor xenograft model. It involves the injection of tumor cells in a mouse to generate solid xenografts beneath the skin. Subsequent injection of fluorescent antibodies confirms specific localization through enhanced fluorescence signals within the tumor xenograft.
03:32
An In Vitro Artificial Activation Assay for Studying Fc Receptor Activation by Antibodies
0 Views •
2025
This video demonstrates FcγRIIIa-driven events initiated by therapeutic antibodies in human natural killer cells. The artificial stimulation platform facilitates the exploration of downstream effector functions, encompassing cytoskeletal rearrangement, degranulation, chemokine/cytokine production, and signaling pathways mediated by the FcγRIIIa and Fc portions of antibodies involved in binding.
02:44
An In Vivo Technique to Track Bispecific Antibody-Induced T Cell Trafficking to Tumors
0 Views •
2025
This video demonstrates a method for tracking bispecific antibody-induced T cell trafficking to tumors in a mouse model. Luciferase-transduced effector T cells are injected into a mouse with a subcutaneous tumor cell xenograft. Bispecific antibodies are then introduced, binding to T cells and the tumor cells. The localization of the T cells is tracked using bioluminescent imaging, with the magnitude of the signal indicating the extent of T cell infiltration into the tumor.
FAQs
The effects may arise through direct killing of malignant cells, interruption of cell-cycle progression, induction of apoptosis, reduced angiogenesis, or enhanced immune recognition. These mechanisms act at different points in tumor development and survival. Distinguishing them helps researchers determine how a treatment works and supports the rational design of chemotherapy, targeted therapies, immunotherapies, and combinations.
Blocking cell-cycle progression can limit the ability of malignant cells to multiply, even when a treatment does not immediately destroy them. Researchers therefore consider growth inhibition alongside direct cell killing and apoptosis. This distinction helps characterize treatment effects more precisely and may clarify whether a candidate primarily suppresses expansion, promotes cell death, or produces both outcomes.
Suppressing angiogenesis can restrict the tumor-supporting process associated with blood-vessel formation, while activating immune recognition can help the body identify tumor cells as targets. These mechanisms extend evaluation beyond direct toxicity to malignant cells. Their inclusion is especially relevant when studying therapies intended to influence the tumor environment or the interaction between cancer cells and host defenses.
A direct effect targets malignant-cell survival or proliferation through processes such as killing, cell-cycle blockade, or apoptosis. An immune-mediated effect instead depends on activating recognition of tumor cells. Separating these possibilities helps researchers interpret response patterns and compare treatment strategies, particularly when assessing targeted therapies, immunotherapies, or combinations with different biological points of action.
Evaluation can progress from cultured cancer cells to animal models and then to clinical studies. Across these settings, researchers examine whether a treatment changes tumor growth, produces regression, affects metastasis, or alters treatment response. Using multiple model levels allows findings from controlled experimental systems to be considered alongside responses observed in living organisms and patients.
Key outcomes include changes in tumor growth, tumor regression, metastasis, and overall treatment response. Together, these measures show whether a treatment merely slows expansion, reduces established tumor burden, limits spread, or produces a broader response. Examining several outcomes provides a more complete assessment than relying on a single indicator of therapeutic effect.
It is relevant when researchers seek to optimize chemotherapy, targeted therapies, immunotherapies, or combinations of these approaches. Comparing treatment responses can help identify whether combining strategies improves control of tumor growth, regression, metastasis, or other measured outcomes. This work also helps clarify potential limitations, guiding further development rather than assuming that every active treatment will be universally effective.